Biodesix Inc
NASDAQ:BDSX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.19
2.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biodesix Inc
Biodesix Inc
Non-Reccuring Items
Biodesix Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biodesix Inc
NASDAQ:BDSX
|
Non-Reccuring Items
-$44k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Non-Reccuring Items
-$10.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
4%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Non-Reccuring Items
-$69m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
-13%
|
|
|
CVS Health Corp
NYSE:CVS
|
Non-Reccuring Items
-$1.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-12%
|
|
|
Cigna Corp
NYSE:CI
|
Non-Reccuring Items
-$2.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-74%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Non-Reccuring Items
-$389.2m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-35%
|
|
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
See Also
What is Biodesix Inc's Non-Reccuring Items?
Non-Reccuring Items
-44k
USD
Based on the financial report for Dec 31, 2023, Biodesix Inc's Non-Reccuring Items amounts to -44k USD.
What is Biodesix Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
52%
Over the last year, the Non-Reccuring Items growth was 99%.
You don't have any saved screeners yet
